Xolair 150 mg Injection (Omalizumab) is a monoclonal antibody therapy licensed for chronic spontaneous urticaria (CSU) and moderate to severe allergic asthma that does not respond adequately to standard treatments. By binding to IgE antibodies, Xolair stops the allergic cascade and reduces symptoms like wheals, itching, and airway inflammation.

Each vial contains 150 mg of Omalizumab for subcutaneous injection, typically administered every 2 or 4 weeks, based on patient weight and baseline IgE levels. Healthcare professionals give injections in a clinical setting to monitor possible allergic reactions post-dose.

Xolair helps reduce reliance on oral antihistamines or corticosteroids in urticaria, and decreases severe asthma exacerbations, improving quality of life. Patients experience fair onset of action within weeks of starting therapy.

Common side effects include injection-site reactions, headache, and mild viral infections. Rare but serious effects may involve anaphylaxis—patients remain under observation after each dose.

Store unused vials in a refrigerator at 2°C to 8°C, protect from light, and allow them to reach room temperature before injection.